Health authorities in Pakistan dismissed claims of a nationwide insulin crisis, clarifying that global supply issues have only affected a single brand named Apidra. Online statements previously warned that the scarcity put Type 1 diabetes patients throughout Pakistan at risk.
Sajid Shah, a ministry spokesperson, verified that Sanofi manufactures Apidra, known scientifically as insulin glulisine, which has disappeared from pharmacies. Yet, he noted that two substitute rapid-acting options, Novo Nordisk products like NovoRapid (insulin aspart) and Eli Lilly items such as Humalog (insulin lispro), stay stocked throughout the country. Shah added that all other main insulin types remain fully obtainable in Pakistan.
The Drug Regulatory Authority of Pakistan supported the statement made by the ministry. Both organizations advised individuals currently using Apidra to speak with their doctor prior to changing brands. They cautioned that altering insulin varieties demands precise dosage changes and strict observation to keep blood sugar levels steady.
The International Diabetes Federation notes that Pakistan hosts roughly 34 million diabetes patients, placing it third worldwide behind India and China. More than 100,000 individuals among them suffer from Type 1 diabetes, needing daily insulin injections to stay alive. Separately, the Pakistan Medical Association stated in August 2025 that a minimum of 80 critical drugs had vanished from shelves, leaving 25 without any replacements.
Authorities have also worked on permanent fixes for frequent insulin shortages. In 2025, the Drug Regulatory Authority of Pakistan permitted Genetics Pharmaceuticals to bring in insulin produced by the Russian firm Zavod Medisintez. Leaders have also conducted senior-level discussions regarding partnerships between Russian and Pakistani drug manufacturers. Specialists point out, nonetheless, that domestic production is the sole dependable permanent remedy because recurring shortages have affected Pakistan about every few months starting in 2023.
